Table 1. Antiprion Potency (ELISA) and Cell Viability (Calcein AM) for Arylamide Analogues.

| R1 | Y | Z | R2 | ELISA EC50 ± SEM (nM) | calcein AM LD50 (nM) | n | |
|---|---|---|---|---|---|---|---|
| 15 | phenyl | CH | CH | Me | 520 ± 173 | >5000 | 3 |
| 16 | phenyl | CH | CH | Et | 221 ± 95 | >9000 | 3 |
| 17 | phenyl | CH | CH | iPr | 22 ± 4 | >10000 | 4 |
| 20 | 2-pyridyl | CH | CH | Et | 365 ± 70 | >10000 | 3 |
| 21 | 3-pyridyl | CH | CH | Et | 243 ± 29 | >10000 | 3 |
| 22 | 4-pyridyl | CH | CH | Et | 743 ± 25 | >10000 | 3 |
| 23 | 2-pyridyl | CH | CH | iPr | 165 ± 31 | >10000 | 3 |
| 24 | 2-pyridyl | N | CH | iPr | 348 ± 129 | >10000 | 3 |
| 25 | 2-pyridyl | CH | N | iPr | 677 ± 195 | >10000 | 4 |
| 26 | 2-pyridyl | CF | CH | iPr | 411 ± 123 | >10000 | 3 |
| 27 | 2-pyridyl | CH | CF | iPr | 334 ± 59 | >10000 | 3 |